Company / Cash & Equivalents
Aclaris Therapeutics, Inc. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$20.0M
FY2025
5-year range
$20.0M / $45.3M
FY2021-FY2025
Trend
-18.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 3 consecutive years, from $45M in FY2022 to $20M in FY2025.
Based on SEC 10-K filings.
$20M in FY2025 with a 5-year CAGR of -2.0%.
Declined from $40M to $20M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -23.9%
- 5-Year CAGR
- -2.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- Aclaris Therapeutics, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 5-year CAGR of -2.0%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 18.8% year-over-year.
- Peak cash & equivalents was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $20.0M | -18.8% |
| FY2024 | $24.6M | -38.4% |
| FY2023 | $39.9M | -11.9% |
| FY2022 | $45.3M | +65.6% |
| FY2021 | $27.3M | +24.0% |
| FY2020 | $22.1M | - |
| FY2019 | - | - |
| FY2018 | $168.0M | +456.7% |
| FY2017 | $30.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026